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Hepatitis delta virus (HDV) is a defective virus requiring the hepatitis B virus (HBV) to provide hepatitis B surface antigens
as the envelope protein. The hepatitis B surface antigens are posttranslationally modified by N-linked glycosylation, and its
significance in HDV assembly was investigated with a cotransfection system using human hepatoma cell line Huh-7. After
the N-linked glycosylation of HBsAg was blocked by tunicamycin treatment, the packaging of HDV in the culture system
could be suppressed to a level as low as 5–10% of the untreated control. The extent of inhibition correlated with the
increased concentrations of tunicamycin. In contrast, the loss of HBsAg glycosylation did not affect the efficiency of assembly
of HBV particles. When the N-linked glycosylation site of small HBsAg at amino acid 146 was mutated from asparagine to
glutamine, the mutant HBsAg packaged only a modest amount of HDV particles. The quantity and kinetics of formation of
HDV particles in culture system were reduced by the depletion of HBsAg glycosylation. Therefore HDV, similar to influenza
and vesicular stomatitis viruses, depends on glycosylation of the envelope proteins as a signal for envelope protein matura-
tion and for virion formation. q 1996 Academic Press, Inc.
INTRODUCTION HBsAg, which are translated from the same open read-
ing frame using three different initiation codons but
Hepatitis delta virus (HDV) infection causes acute or with different efficiencies. Each of the three HBsAgs
chronic hepatitis in humans (Hoofnagle, 1989; Rizzetto, exists in two forms, the glycosylated and the nonglyco-
1983; Taylor, 1991). Clinical and animal studies have sylated form (Heermann et al., 1984; Peterson, 1982;
shown that natural transmission of HDV always requires Stibbe and Gerlich, 1983). The large HBsAg is required
the presence of hepatitis B virus (HBV) (Ponzetto et al., for hepatocyte infection by HDV (Sureau et al., 1993),
1984; Rizzetto, 1983), either by superinfection in hepatitis just as it is required by HBV (Neurath et al., 1986; Pon-
B carriers or by coinfection with HBV (Hoofnagle, 1989; tisso et al., 1989). However, the HDV virion assembly
Rizzetto et al., 1980). The dependence on HBV is an inher- in vitro requires neither the large nor the middle HBsAg,
ent characteristic of HDV. HDV virion is a 36-nm particle differing from HBV assembly which requires both the
composed of four essential components. It contains a large and the small HBsAg (Bruss and Ganem, 1991;
single-stranded, circular RNA genome of 1.7 kb in length Ganem, 1991). Cotransfection experiments have shown
(Kos et al., 1986; Makino et al., 1987; Wang et al., 1986) that small HBsAg only is sufficient for HDV packaging
and two nucleocapsid proteins encoded by the viral ge- (Ryu et al., 1992; Wang et al., 1991). We further deter-
nome, namely the large and the small hepatitis delta mined the minimal domain of HBsAg in participating in
antigens (HDAgs) (Bonino et al., 1986). The fourth compo- the HDV assembly, and the results indicated that a C-
nent, the viral envelope protein, however, is not encoded terminus-truncated HBsAg had lost its capability for
by the viral genome but is provided by HBV (Bonino et al., assisting HDV assembly (Chen et al., 1993).
1986; Rizzetto et al., 1980). Hepatitis B surface antigens To extend the previous work, we present in this report
(HBsAgs) not only form the HDV envelope but also deter- that this C-terminus-truncated HBsAg exists only in the
mine the cell tropism of HDV infection. And thus, HDV nonglycosylated form, which is in contrast to the wild-
could be considered a defective virus under HBV pseu-
type HBsAg. As posttranslational modification of a pro-
dotype (Ponzetto et al., 1984; Rizzetto et al., 1980).
tein is sometimes very crucial for its function, our obser-
The role of HBsAg in HDV infection and assembly
vation raised a possibility that the glycosylation of HBsAg
has been investigated in some detail (Ryu et al., 1992;
might be important for HDV assembly. We therefore ex-
Sureau et al., 1993; Wang et al., 1991). There are three
amined the effect of HBsAg glycosylation on its capabilityforms of HBsAgs, the large, the middle, and the small
for HDV assembly. The results indicated that the glyco-
sylation of HBsAg appeared to be important, though not
essential, in directing HDV assembly.1 To whom reprint requests should be addressed.
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MATERIALS AND METHODS
Plasmids
Plasmid pSVLD3, bearing sequences of HDV cDNA
trimer under the control of simian virus 40 late promoter,
was used to initiate HDV RNA replication and the expres-
sion of HDAgs in transfection experiments (Kuo et al.,
1989). Plasmid pHBV48, a partial dimer of HBV DNA,
was used in transfection experiments to produce HBV
particles (H.-L. Wu et al., 1991). Plasmid pDPSX con-
taining the small HBsAg-encoding open reading frame
(ORF) under the control of HBV endogenous pre-S1 pro-
moter was used to express the small form HBsAg as
previously described (Wang et al., 1991). Plasmid pSX-
50 expressing HBsAg with a truncation of 50 amino acids
at the C-terminus was derived from pDPSX which was
cleaved by a restriction enzyme, SpeI, recognizing resi- FIG. 1. DNA sequencing of a mutant small HBsAg gene and immu-
due 175 in the ORF of HBsAg, and made blunt by provid- noblotting of its protein product. (A) Nucleotide and encoded amino
acid sequences of the mutant-expressing plasmid pSX-50 are showning three (A, T, C) instead of four (A, T, C, G) kinds of
at the bottom, compared with those of the wild-type HBsAg shown atnucleotides for making a stop codon at the SpeI site
the top. The construction of the plasmid pSX-50 is described under(Chen et al., 1993). However, the truncated HBsAg con-
Materials and Methods. The mutant has a deletion of 10 nucleotides
tained 4 amino acid residues not equal to the original (nt), resulting in joining of nt 680 to nt 691. Due to the frame shifting,
due to the frame-shift mutation caused by the Klenow 4 irrelevant amino acid residues were added, and a stop codon was
created thereafter. This construct expressed the HBsAg with truncationfragment treatment as shown in Fig. 1A.
of 50 amino acids at the C-terminus. SpeI cutting site is indicated byTo prepare a plasmid expressing the mutant form of
an arrow. (B) The C-terminus-truncated HBsAg particles (MT) collectedsmall HBsAg defective in glycosylation, amino acid 146
from culture medium of transfected Huh-7 cells treated with or without
was changed by recombinant PCR from Asn to Gln, thus tunicamycin were subjected to Western blot analysis (lanes 3 and 4).
losing the consensus motif Asn-Cys-Thr for N-linked gly- As a control, the wild-type (WT) small HBsAgs (expressed by pDPSX)
obtained from the culture medium of transfected Huh-7 cells treatedcosylation. Two pairs of primers were designed. The se-
without or with tunicamycin were assayed (lanes 1 and 2). Positionsquences for these four primers in relation to HBV se-
of the glycosylated (gp27) and the unglycosylated (p24) small HBsAgsquence (adw subtype and EcoRI site as nucleotide 1)
are marked.
were as follows: primer 44, 5*-CACAACCTTCCACCA-3*
(nt 2–16); S2, 5*-TAAATGGAGCAGCAAACCCC-3* (1030 –
1010); N1, 5*-CTACGGATGGACAGTGCACC-3* (577– for 20 hr; the culture medium was then replaced with
596); and Nr, 5*-GGTGCACTGTCCATCCGTAG-3* (596 – fresh DMEM or DMEM containing different concentra-
577). Primers N1 and Nr were complementary to each tions of tunicamycin (0.2, 1.0, or 2.0 mg/ml medium, pur-
other and within the sequences the codon for Asn (AAT, chased from Sigma). The cultured media were collected
nt 588–590) was mutated to CAG for Gln shown as every 3 days and further refreshed with DMEM con-
underlined. For first PCR reaction, 44 was paired with Nr taining the same concentration of tunicamycin until Day
while N1 was paired with S2; plasmid pS1X (Wang et al., 9 or Day 12.
1991), containing the entire HBsAg gene, was used as
a DNA template. The PCR products were eluted sepa- DNA transfection
rately and used as templates for the recombinant PCR
DNA transfection was performed by the calcium phos-reaction with oligonucleotides 44 and S2 as primers. The
phate method (Graham and van der Eb, 1973). Huh-7resulting PCR product was digested with SpeI and EcoRI
cells were seeded at a density of 4.5 1 106 cells perand then used to replace the corresponding region of
100-mm diameter dish and grown to 80% confluence.plasmid pDPSX, yielding the new construct, pSX-N. DNA
Ten micrograms of plasmid DNA were transfected ontosequencing was performed to confirm that only this site
the cells. In some transfection experiments, plasmid DNAwas mutated.
expressing HBsAg was included and the culture medium
was assayed for HBsAg production, used as a control ofCell culture and tunicamycin treatment
transfection efficiency described previously (Wang et al.,
1994). The amount of HBsAgs was determined by a com-Huh-7 cells were cultured in the Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum mercial enzyme-linked immunoassay (IMX; Abbott Labo-
ratories, North Chicago, Ill.) and expressed as S/N ratios(Gibco). For glycosylation-blocking experiments, trans-
fected cells were incubated at 377 in a 5% CO2 incubator (Wang et al., 1994).
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Viral particle purification or 2.0 mg/ml tunicamycin, respectively) was quantified by
Southern blot analysis. HBV particles collected from the
The culture media were collected on Days 3, 6, and 9 culture media were spun down and treated with Staphy-
(or until Day 12 in certain experiments) posttransfection. lococcus aureus nuclease to remove residual DNA out-
Viral particles were spun down through a 20% sucrose side the particles. The particles were digested with 0.5
cushion in an SW28 rotor by centrifugation at 25,000 mg/ml proteinase K in 0.5% SDS at 507 for 2 hr. After
rpm and 47 for 17 hr (Beckman L-8). The pellets were phenol/chloroform extraction, nucleic acids were ob-
resuspended in an appropriate volume of phosphate- tained by ethanol precipitation. The HBV DNA samples
buffered saline (PBS) proportional to the S/N ratio of were subjected to 1% agarose gel electrophoresis in 11
HBsAg production (usually 200–300 ml for viral particles TBE (101 TBE is 0.9 M Tris, 0.9 M borate, 0.02 M EDTA,
obtained from 10 ml culture media) (Wang et al., 1991). pH 8.3; purchased from BDH) overnight and the gel was
then treated with standard denaturation and neutraliza-RNA isolation and Northern blot analysis
tion procedures (Southern, 1975). DNA was then electro-
transferred to a membrane and hybridized with a ribo-Viral particles were diluted in 11 TE buffer (1 mM Tris,
probe complementary to the HBV plus-strand DNA, whichpH 8.0; 0.1 mM EDTA, pH 8.0) and then treated with 0.5
specifically detects the DNA in mature virions (Hayashimg/ml proteinase K in 0.5% SDS. After phenol/chloroform
and Koike, 1989).extraction and alcohol precipitation, viral RNAs were ana-
lyzed by Northern blot. The RNA samples were glyoxa-
RESULTSlated (1 M glyoxal; 50% DMSO; 10 mM phosphate buffer
at pH 6.8) at 507 for 1 hr and then electrophoresed in a
Characterization of a small HBsAg mutant defective
1% agarose gel made of PBS (10 mM, pH 6.8). The re-
in glycosylation and in assisting HDV packaging
solved RNAs were electrotransferred in 141 TAE buffer (1
It has been demonstrated that among the three formsmM Tris, 0.025 mM EDTA, 0.5 mM acetic acid, pH 8.0;
(large, middle, and small) of HBsAg, the small-formpurchased from BDH) to a nylon membrane (Zeta probe,
HBsAg alone is sufficient in assisting HDV assembly (RyuBio-Rad) and then hybridized with a specific probe. An
et al., 1992; Wang et al., 1991). In order to more preciselyantigenomic riboprobe was used for detecting genomic
define the essential minimum domain, we constructed aHDV RNA as previously described (Wang et al., 1991).
series of deletion mutants of small HBsAg and tested
Western blot assay their capability for assisting HDV assembly. One mutant
(pSX-50) with truncation of 50 amino acids at the C-termi-
The viral particles collected and pelleted from culture nus (Fig. 1A) was found unable to assist HDV assembly
media as described above were resuspended in PBS (Chen et al., 1993), thus displaying an interesting prop-
buffer and prepared for Western blot analysis. For total erty.
cell lysates, cells were harvested, mixed with 10 volumes Huh-7 cells were transfected with pSX-50 and the cul-
of 21 SDS sampling buffer (0.125 M Tris–Cl, pH 6.8; 4% ture media were collected to harvest the HBsAg particles
SDS; 2% glycerol; 10% 2-mercaptoethanol; 0.02% bromo- (Chen et al., 1993). Immunoblot analysis of such particles
phenol blue), and then sonicated for 30 sec (sonicator with antibody specific to HBsAg identified only one spe-
SONIPREP 150, amplititude 15 mm). The samples were cies of this truncated HBsAg with a predicted size (Fig.
boiled for 10 min and then separated in a vertical SDS – 1B, lane 3). In contrast, cells transfected with plasmid
PAGE (12%). The antibodies used for viral protein detec- pDPSX expressing wild-type small HBsAg produced two
tion included a primary monoclonal antibody against forms of HBsAg, the unglycosylated (p24) and the glyco-
HBsAg, A10F1 (provided by Dr. Sheng-Chung Lee, Gradu- sylated (gp27) forms (Fig. 1B, lane 1). The lack of a higher
ate Institute of Molecular Medicine, National Taiwan Uni- molecular weight species in the mutant HBsAg sug-
versity, College of Medicine), used at a 1:300 dilution gested that it might not be glycosylated. To test this, a
(Wang et al., 1991), and patient-derived polyclonal antise- glycosylation inhibitor, tunicamycin, was added into the
rum against HDAg (Chang et al., 1991), used at a 1:1000 medium of transfected Huh-7 cells with a concentration
dilution. The secondary antibodies were horseradish per- of 1 mg/ml. The HBsAg particles were similarly recovered
oxidase-conjugated sheep antibodies against murine or from culture medium on Day 3 posttransfection and ana-
human immunoglobulin (purchased from Amersham) and lyzed by immunoblotting. Results shown in Fig. 1B indi-
used at a 1:5000 dilution. Reacted proteins were visual- cated that cells transfected with pDPSX produced only
ized by chemiluminescence using the ECL system (Amer- the unglycosylated form of small HBsAg after tuni-
sham). camycin treatment (lane 2); however, cells transfected
with pSX-50 produced the identical protein either in theSouthern blot assay
absence or in the presence of tunicamycin (lanes 3 and
4, respectively). The results indicated that this mutantThe production of HBV particles in the transfected
Huh-7 cells with or without tunicamycin treatment (0, 1.0, HBsAg could not be glycosylated.
AID VY 7922 / 6a17$$$$62 04-30-96 07:58:27 vira AP: Virology
31HEPATITIS B sAg GLYCOSYLATION IN HDV ASSEMBLY
There could be three reasons why the mutant HBsAg HDAg (about 40%) was noted in cells treated with a high
dose of tunicamycin. Therefore the pSVLD3 alone-could not assist HDV assembly. First, the mutant form of
HBsAg lost the ability of assembling into a particle. Sec- transfected Huh-7 cells with different concentrations of
tunicamycin were also analyzed for the production ofond, the C-terminal sequences of HBsAg were crucial
for HDV particle formation. Third, the glycosylation of HDAg. There were no variations in the levels of the large
and the small HDAg until Day 12 posttransfection (dataHBsAg was important for HDV assembly. As the HBsAg
particles from the medium of cells transfected with pSX- not shown), which ruled out the possibility that both the
large and the small HDAg were directly influenced by50 were able to be banded at a density of 1.17–1.20 g/
cm3 in a CsCl gradient obtained by isopycnic centrifuga- the effect of tunicamycin. In addition, production of
HBsAg was also not adversely affected by adding tuni-tion (data not shown), the first possibility was ruled out.
Both the second and the third reasons are possible and camycin up to a concentration of 2 mg/ml (Fig. 3B), which
was consistent with previous data (Patzer et al., 1984;warrant further investigation. It has been shown that a
posttranslational modification, isoprenylation, of the C- Sheu and Lo, 1994; Lu et al., 1995) that inhibition of
glycosylation by tunicamycin did not affect secretion ofterminus of large HDAg is essential for HDV assembly
(Glenn et al., 1992; Hwang and Lai, 1993; Lee et al., 1994). HBsAgs from mammalian cells. About 20–30% of cells
showed degenerative changes on Day 9 in the case ofThis prompted us to study the significance of HBsAg
glycosylation in the morphogenesis of the HDV particle. 2 mg/ml tunicamycin treatment, but the other cells ap-
peared quite normal below this concentration of tuni-
camycin.A potent suppressing effect of tunicamycin on HDV
The experiments were repeated several times and aassembly
summary is shown in Fig. 3A. The amount of packaged
HDV RNA was normalized to the amount of HBsAg in theTo explore such a possibility, HDV assembly was ex-
amined in the presence of tunicamycin. Plasmid pDPSX particles. In the presence of 0.2 mg/ml tunicamycin, HDV
packaging was reduced to 37% of the untreated on Day(expressing wild-type small HBsAg) was cotransfected
with pSVLD3 (for initiating HDV replication) into Huh-7 6 and to 70% on Day 9 posttransfection. When the con-
centration was increased to 1 mg/ml medium, the pack-cells cultured with different concentrations of tuni-
camycin. Both the medium and the cell lysates were aging level was further reduced to 6% on Day 6 and to
18% on Day 9 posttransfection. The extent of inhibitioncollected on Day 6 and Day 9 posttransfection. Proteins
and RNAs were analyzed from both the viral particles of HDV assembly correlated with the degree of HBsAg
deglycosylation (Fig. 2, lanes 2–4 and lanes 6–8, topand the cell lysates. As anticipated, increased concentra-
tions of tunicamycin in the culture media resulted in a left). It indicated a dose-dependent correlation for the
degree of inhibition of HDV packaging with tunicamycincorresponding loss of the glycosylated form of small
HBsAg both in the particles (Fig. 2, lanes 2–4, top left) concentrations and suggested that the glycosylation of
HBsAg might be important in HDV assembly.and in the cell lysates (lanes 2–4, top right).
Interestingly, immunoblot analysis of proteins from the Nevertheless, it was noted that even in the continuous
presence of tunicamycin, the amount of HDV producedparticles revealed a dramatic decrease of HDAgs pack-
aged after tunicamycin treatment. In the absence of tuni- gradually increased from Day 6 to Day 9 posttransfection
(Fig. 2, lane 2 versus lane 6, middle and bottom left). Thecamycin, both the large and the small HDAgs were pack-
aged efficiently into the particles (Fig. 2, lanes 1 and 5, results indicated that glycosylation of HBsAg, although
influencing the efficiency of HDV assembly profoundly,middle left). However, in the presence of tunicamycin,
the HDAgs were no longer detected in the particles (Fig. was not essential for the packaging of the HDV particle.
2, lanes 2–4, middle left). Only a very little amount of
HDAgs was packaged on Day 9 posttransfection from No effect of tunicamycin treatment on HBV
Huh-7 cells treated with 0.2 mg/ml tunicamycin (Fig. 2, production
lane 6, middle left). Northern blot analysis of the pack-
aged HDV RNA in the particles yielded a similar result: The aforementioned studies suggested that tuni-
camycin treatment exerted a specific inhibitory effect onthe increased concentrations of tunicamycin profoundly
reduced the amount of HDV packaged RNA (Fig. 2, lanes HDV assembly; however, it did not affect the formation
of HBsAg particles as is summarized in Fig. 3B. Since2–4 or lanes 6–8, bottom left).
The reduced efficiency of HDV packaging after tuni- the formation and release of HBsAg particles were not
affected, the suppression of HDV assembly by tuni-camycin treatment, however, was not due to a decrease
of HDV replication in the treated cells, since the levels camycin was not secondary to an adverse effect on the
general secretion or the release pathway of the particles.of the large and the small HDAgs (Fig. 2, lanes 1–8,
middle right) and of HDV RNA (Fig. 2, lanes 1–8, bottom However, the HBsAg particles we used in this experiment
were actually empty virus-like particles that did not con-right) in the treated cells were found equivalent to those
in the untreated cells. Occasionally, a decrease of large tain viral genome (Ganem, 1991; Tiollais et al., 1985); it
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FIG. 2. Analysis of HDV RNA and protein from the virions and the transfected cells with or without tunicamycin treatment. Huh-7 cells were
transfected with pDPSX plus pSVLD3 in the presence of different concentrations of tunicamycin ranging from 0, 0.2, 1.0, to 2.0 mg/ml medium. (Left)
The HDV virions collected from culture media on Day 6 (lanes 1–4) and Day 9 (lanes 5–8) posttransfection were analyzed for their HBsAg envelope
(top) and HDAg (middle) by Western blot analyses and HDV RNA (bottom) by Northern blot analysis. (Right) Similar analyses from cell lysates.
Molecular masses are in kilodaltons in Western blot analyses and in kilobases in Northern blot analyses. Migration of marker proteins and HDV
RNA used as positive control (PC) is represented on the left lanes.
was therefore necessary to determine whether or not the Small HBsAg mutated at the glycosylation site is
ineffective in assisting HDV assemblypathway for complete virion assembly (containing viral
genome) was affected by tunicamycin treatment. Although the data obtained from tunicamycin treatment
To address this question, the production of complete led to an inefficient HDV assembly, whether this was due
HBV particles from the transfected Huh-7 cells treated to the loss of glycosylation of HBsAg rather than the loss
with tunicamycin was determined. Plasmid pHBV48 of glycosylation of other cellular proteins needed to be
which can initiate HBV production (H.-L. Wu et al., 1991) confirmed. To address this, we constructed a plasmid
was transfected alone or cotransfected with pSVLD3 into expressing a small HBsAg mutant which would not be
Huh-7 cells in the presence of tunicamycin. Viral particles glycosylated due to mutation of the glycosylation site
were purified from culture media on Day 3 and Day 6 at amino acid 146 (from asparagine to glutamine). The
posttransfection. The amount of the complete HBV parti- advantage of using this mutant plasmid (pSX-N) to study
cles was quantified by Southern blot analysis of HBV HDV assembly was that it specifically addressed the im-
DNA. The levels of HBV DNA in the particles released portance of HBsAg glycosylation in HDV assembly and
from Huh-7 cells remained unchanged, regardless of the precluded all the nonspecific effects of tunicamycin on
presence of different concentrations of tunicamycin (Fig. cells.
4, lanes 1–6, second blot). This result indirectly ruled As shown in Fig. 5 (lanes 1–4, top left), after cotrans-
out the concern that deglycosylated HBsAg might fail to fection of pSX-N with pSVLD3 into Huh-7 cells, this mu-
assemble into virions. Consistent with previous results, tant plasmid produced only the unglycosylated form of
the packaging of HDV proteins and RNA was profoundly HBsAg (p24), in contrast to plasmid pDPSX which pro-
inhibited by tunicamycin (Fig. 4, comparing lane 4 versus duced both glycosylated (gp27) and unglycosylated (p24)
lanes 5 and 6, third and fourth blots). The results thus HBsAgs (lanes 5–8). Viral particles isolated from culture
favored a specific effect of HBsAg deglycosylation on media on Days 3, 6, 9, and 12 posttransfection were used
for HDV detection.HDV assembly.
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FIG. 3. (A) Relative level and time course of HDV assembly in the presence of different concentrations of tunicamycin. Viral particles collected
from culture supernatant on Day 6 and Day 9 posttransfection were analyzed for HBsAg and HDV RNA contents. The amount of packaged HDV
RNA was quantitated by densitometer tracing signals in the Northern blot and then normalized to the amount of HBsAg. The relative level of HDV
assembly at a specific concentration of tunicamycin was expressed as a ratio of its densitometric value to the value of that without tunicamycin
treatment and drawn as a bar graph. The analyses were repeated three times by using different samples (data not shown) and the deviation is
indicated on the top of each bar. (B) Temporal profile of HBsAg production by Huh-7 cells after transfection in the presence of tunicamycin. The
small HBsAg-expressing plasmid pDPSX was cotransfected with pSVLD3 in the presence of different concentrations of tunicamycin ranging from
0, 0.2, 1.0, to 2.0 mg/ml, respectively. The culture media were collected on Days 3, 6, and 9 posttransfection. The production of HBsAg was determined
by checking a 0.2-ml aliquot of each different sample with an automatic commercial enzyme-linked immunoassay and expressed as S/N ratios
(sample versus negative control). Each point represents the mean of at least two independent experiments.
As noted previously, HDV particles usually appear in 8, middle and bottom left). When the Northern blot analy-
sis of packaged HDV RNA was traced by densitometer,culture medium on Days 6 –9 posttransfection when wild-
type HBsAg-expressing plasmid is used in the cotrans- the results indicated that only 5 to 10% of HDV packaging
occurred compared with HDV packaging by using wild-fection system (Wang et al., 1991) (Fig. 5, lanes 6 and
7, middle and bottom left). However, when the plasmid type HBsAg (Fig. 5, lanes 3 and 4 versus lanes 7 and 8,
middle and bottom left). However, in the cells, HBsAg,expressing the glycosylation-defective HBsAg was used
in the cotransfection experiments, the amount of HDV HDAg, and HDV RNA remained at similar levels in the
wild-type and the mutant HBsAg-transfected cell linesparticles produced was much less than those packaged
by wild-type HBsAg (Fig. 5, lanes 1–4 versus lanes 5– (Fig. 5, lanes 1–8, top, middle, and bottom right).
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sembly. In the process of HDV assembly, both the in vivo
transfection and the in vitro experiments suggested that
HBsAgs can interact with the large HDAg alone (Chang
et al., 1991; Hwang and Lai, 1993). The domain of HBsAg
responsible for this interaction is not yet identified. How-
ever, because the intact HBsAg particles were incapable
of interacting with the large HDAg, while the denatured
HBsAg could (Hwang and Lai, 1993), it is suggested that
the large HDAg did not interact with the HBsAg domains
exposed on the particles but instead interact with the
domains inside the particles. As the oligosaccharide
complex of HBsAg is located at the ‘‘a’’ epitope which is
exposed on the particles (Stirk et al., 1992), it should
not interact directly with the large HDAg. Therefore the
glycosylation probably does not affect the interaction be-
tween the two proteins. In fact, we tested the effect of
tunicamycin on the assembly of HBsAg-like particles
containing large HDAg only (instead of complete HDV
virions) and indeed found no suppression at all (data not
shown). Thus the observed effect of HBsAg glycosylation
on HDV assembly is probably secondary to a weakened
interaction between deglycosylated HBsAg and the com-
ponents of HDV other than large HDAg.
Following the time course of HDV formation in the
cotransfection experiments, we found a gradual recovery
of HDV assembly in the absence of HBsAg glycosylation.FIG. 4. Detection of HBV and HDV production from transfected Huh-
Modest amounts of HDV particles were finally released7 cells upon tunicamycin treatment. Both HBV and HDV particles pro-
duced by Huh-7 cells cotransfected with plasmid pHBV48 and pSVLD3 on Day 9 or Day 12, in the experiments using either
in the presence of different concentrations of tunicamycin were ob- tunicamycin treatment (Fig. 2, lane 2 versus lane 6, mid-
tained on Day 3 (lanes 1–3) and Day 6 (lanes 4–6) posttransfection.
dle and bottom left) or glycosylation-defective HBsAgThe packaged HBV DNA was analyzed by Southern blot analysis and
(Fig. 5, lanes 1–4, middle and bottom left). Therefore,HBsAg by immunoblotting. The amount of HDV production was deter-
another possibility is that glycosylation may influence themined by the detection of HDV RNA and HDAgs.
maturation or the trafficking of HBsAg in the cells, thus
affecting its capability or rate in interacting with HDV
The data strongly suggested that loss of glycosylation components prior to assembly. Recent progress in cellu-
of HBsAg, rather than loss of glycosylation of other cellu- lar biology has found that N-linked glycosylation is an
lar proteins, was responsible for the suppression of HDV important signal in the correct folding and transport of
assembly. However, an effect by the missense substitu- various cellular and viral proteins. In HepG2 and some
tion (Asn to Glu) of HBsAg could not be excluded in the other cell lines, many newly synthesized monomeric gly-
current study. coproteins (such as antitrypsin, transferrin) were tran-
siently associated with a molecular chaperone termed
calnexin localized in the endoplasmic reticulum (ER)DISCUSSION
membrane during protein maturation (Degen and Wil-
liams, 1991; Hochstenbach et al., 1992; Ou et al., 1993).Previous studies have shown that HBsAg is essential
for HDV assembly (Ryu et al., 1992; Wang et al., 1991; Association of glycoproteins with calnexin ensures their
correct folding and enhances their maturation (HammondJ.-C. Wu et al., 1991). In this study, we further found that
not only the HBsAg but also its posttranslational modifi- et al., 1994; Ou et al., 1993). Such an interaction with
calnexin requires the presence of N-linked oligosaccha-cation, namely the N-linked glycosylation, was involved in
HDV morphogenesis. Without glycosylation, the HBsAg is ride sidechains of these glycoproteins (Hammond et al.,
1994). Proteins without glycosylation are often misfoldedabout 10-fold less effective in assisting HDV assembly.
However, the production of both HBV and HBsAg parti- and slowed down in their secretion kinetics. In fact, the
importance of protein glycosylation has been shown incles is not influenced. How glycosylation of HBsAg par-
ticipates in HDV assembly is an interesting issue. A sim- the maturation of both the influenza hemagglutinin and
the vesicular stomatitis virus G protein (Hammond andple explanation is that the glycosylated HBsAg pos-
sesses a higher affinity for the other components of HDV Helenius, 1994; Hammond et al., 1994; Hebert et al.,
1995). Therefore inhibition of HBsAg glycosylation couldthan nonglycosylated HBsAg, and thus favors HDV as-
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FIG. 5. Kinetic study of HDV packaging by a small HBsAg mutant (pSX-N) defective in N-linked glycosylation. Plasmid pSVLD3 was cotransfected
with pSX-N, defective in N-linked glycosylation, or with pDPSX, expressing wild-type HBsAg, into Huh-7 cells. (Left) Secreted HDV virions obtained
on Days 3, 6, 9, and 12 posttransfection were subjected to Western and Northern blot assays for analyses of the HBsAg (top), HDAg (middle), and
HDV RNA (bottom). (Right) Cell lysates were also similarly analyzed. Molecular masses and migration of proteins and RNA markers are the same
as in the legend to Fig. 2.
affect the kinetics of virion assembly by influencing matu- of the C-terminal 50 amino acids. The glycosylation motif
or the adjacent sequences of glycosylation site at aminoration and trafficking of the protein component. The
above interpretations do not explain why deglycosylation acid 146 was not affected. However, the mutant was not
glycosylated. Although the topology of HBsAg has beenof HBsAg selectively affects the assembly of HDV only,
but not the formation of HBsAg or HBV particles. It was investigated extensively (Stirk et al., 1992), the exact con-
formation of the C-terminus remains undefined (Brussnoted that one potent inhibitor of oligosaccharide-trim-
ming enzyme, N-butyldeoxynojirimycin, selectively sup- and Thomssen, 1994; Stirk et al., 1992). The property of
this mutant suggested that the C-terminus of HBsAg ispressed the release of HBV particles but not the release
of HBsAg particles (Block et al., 1994; Lu et al., 1995). important in orientating HBsAg in the ER membrane to
become accessible to the glycosylation machinery.These observations suggested that morphogenesis of
the three HBsAg-containing particles probably occurs
through different cellular pathways which are determined
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